Karyopharm Therapeutics Inc. (KPTI) Earns Buy Rating from Cantor Fitzgerald
Karyopharm Therapeutics Inc. (NASDAQ:KPTI)‘s stock had its “buy” rating reaffirmed by investment analysts at Cantor Fitzgerald in a research report issued on Wednesday. They presently have a $18.00 target price on the stock. Cantor Fitzgerald’s price target indicates a potential upside of 61.29% from the stock’s current price.
Other analysts have also recently issued research reports about the company. Robert W. Baird reiterated an “outperform” rating and set a $15.00 price objective on shares of Karyopharm Therapeutics in a research report on Tuesday, July 4th. Royal Bank Of Canada began coverage on Karyopharm Therapeutics in a research report on Thursday, September 14th. They set an “outperform” rating and a $14.00 price objective for the company. Canaccord Genuity set a $18.00 price objective on Karyopharm Therapeutics and gave the company a “buy” rating in a research report on Tuesday, August 8th. ValuEngine cut Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 25th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $16.00 price objective on shares of Karyopharm Therapeutics in a research report on Friday, July 14th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the stock. Karyopharm Therapeutics has an average rating of “Buy” and a consensus target price of $15.67.
Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Tuesday, August 8th. The company reported ($0.64) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.64). Karyopharm Therapeutics had a negative return on equity of 70.42% and a negative net margin of 67,267.47%. During the same period in the previous year, the company earned ($0.84) earnings per share. The firm’s revenue for the quarter was down 95.0% compared to the same quarter last year.
COPYRIGHT VIOLATION WARNING: “Karyopharm Therapeutics Inc. (KPTI) Earns Buy Rating from Cantor Fitzgerald” was published by American Banking News and is owned by of American Banking News. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2017/09/21/karyopharm-therapeutics-inc-kpti-earns-buy-rating-from-cantor-fitzgerald.html.
In other Karyopharm Therapeutics news, Director Mansoor Raza Mirza sold 2,882 shares of the business’s stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $11.00, for a total transaction of $31,702.00. Following the completion of the sale, the director now owns 2,882 shares of the company’s stock, valued at $31,702. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 8,000 shares of company stock valued at $85,024 in the last three months. 14.71% of the stock is currently owned by corporate insiders.
A number of large investors have recently added to or reduced their stakes in KPTI. Vanguard Group Inc. grew its holdings in Karyopharm Therapeutics by 31.1% during the second quarter. Vanguard Group Inc. now owns 1,621,420 shares of the company’s stock valued at $14,675,000 after purchasing an additional 384,658 shares during the period. Teachers Advisors LLC grew its holdings in Karyopharm Therapeutics by 915.0% during the first quarter. Teachers Advisors LLC now owns 420,563 shares of the company’s stock valued at $5,400,000 after purchasing an additional 379,127 shares during the period. Iguana Healthcare Management LLC bought a new stake in Karyopharm Therapeutics during the first quarter valued at about $3,531,000. Candriam Luxembourg S.C.A. grew its holdings in Karyopharm Therapeutics by 154.7% during the second quarter. Candriam Luxembourg S.C.A. now owns 438,000 shares of the company’s stock valued at $3,964,000 after purchasing an additional 266,000 shares during the period. Finally, Palo Alto Investors LLC grew its holdings in Karyopharm Therapeutics by 6.4% during the first quarter. Palo Alto Investors LLC now owns 3,406,475 shares of the company’s stock valued at $43,739,000 after purchasing an additional 206,079 shares during the period. 58.97% of the stock is owned by institutional investors and hedge funds.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.